Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 11 May 2012
In early 2011, several bills aiming to curb drug shortages were introduced in the US House of Representatives and the US Senate. Despite the bills' bipartisan nature and widespread support, they've languished in Congressional committees ever since. Now, reports CBS, there are signs that both bills could see passage before the end of the year.
The bills, House and Senate versions of the Preserving Access to Life-Saving Medications Act (H.R. 2245 & S. 296), would require pharmaceutical manufacturers to notify the US Food and Drug Administration (FDA) of any impending drug shortages.
"Both [political] parties and the President support the bills, yet they haven't passed," reports CBS.
The bills are sponsored by, among others, Sens. Susan Collins (R-ME) and Amy Klobuchar (D-MN), and Reps. Diana DeGette (D-CO) and Tom Rooney (R-FL).
For DeGette, the slow progress on the bills has been a source of constant frustration.
"I have never seen a Congress where it is more difficult to pass legislation," remarked DeGette, who implored CBS to contact the congressional leadership to press them on the issue.
Klobuchar, too, has shown her inpatience in the past. In February, Klobuchar threatened to attach the bill to a must-pass highway bill. At that time, the legislation had already attracted 63 co-sponsors in the House and 23 co-sponsors in the Senate-no small feat in a highly polarized Congress.
Both Speaker of the House John Boehner (R-OH) and Senate Majority Leader Harry Reid (D-AZ) said the legislation will come before their respective full chambers "soon," and CBS notes the legislation could receive committee votes by Memorial Day (28 May 2012).
The bill would provide FDA with the authority to require manufacturers to notify them of impending shortages. A 15 December 2011 report by the Government Accountability Office (GAO) noted FDA lacked the statutory authority to make such requirements of the pharmaceutical industry.
While FDA has instituted a voluntary plan-one which the agency has touted as being widely successful-it still says drug shortages "remain a serious, complex problem."
"The industry has to not be afraid to let FDA know if they have a problem, so that we can get in there and work with them to fix it before it results in a shortage," said Margaret Hamburg, Commissioner of FDA.
Read more:
CBS - Bill that would help curb drug shortages headed for vote after 15-month delay
Regulatory Focus - Hamburg Touts Agency's Efforts to Curb Drug Shortages
Regulatory Focus - GAO Report Finds That FDA Needs Increased Authority to Address Shortages
Regulatory Focus - Senator: Drug Shortage Bill Could Be Bundled With Highway Bill
Tags: Alleviate, PALM Act, House, Shortages, Latest News, Hamburg, Senate, Bill, Congress, pharmaceutical, Reduce, drug
Regulatory Focus newsletters
All the biggest regulatory news and happenings.